{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T07:11:41Z","timestamp":1770275501011,"version":"3.49.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T00:00:00Z","timestamp":1683331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T00:00:00Z","timestamp":1683331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004505","name":"University of Catania","doi-asserted-by":"crossref","award":["PIACERI Linea 2"],"award-info":[{"award-number":["PIACERI Linea 2"]}],"id":[{"id":"10.13039\/501100004505","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-023-02821-x","type":"journal-article","created":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T08:02:17Z","timestamp":1683360137000},"page":"91-102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Low dose rivaroxaban for the management of atherosclerotic cardiovascular disease"],"prefix":"10.1007","volume":"56","author":[{"given":"Placido Maria","family":"Mazzone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5156-7723","authenticated-orcid":false,"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,6]]},"reference":[{"issue":"4","key":"2821_CR1","doi-asserted-by":"publisher","first-page":"786e1","DOI":"10.1016\/j.ahj.2005.11.004","volume":"151","author":"EM Ohman","year":"2006","unstructured":"Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau CS et al (2006) The REduction of atherothrombosis for continued health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J 151(4):786e1\u201378610. https:\/\/doi.org\/10.1016\/j.ahj.2005.11.004","journal-title":"Am Heart J"},{"issue":"12","key":"2821_CR2","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1001\/jama.2010.1322","volume":"304","author":"DL Bhatt","year":"2010","unstructured":"Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM et al (2010) Comparative determinants of 4-Year Cardiovascular Event Rates in stable outpatients at risk of or with atherothrombosis. JAMA 304(12):1350\u20131357. https:\/\/doi.org\/10.1001\/jama.2010.1322","journal-title":"JAMA"},{"issue":"1","key":"2821_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1161\/01.CIR.90.1.61","volume":"90","author":"PA Merlini","year":"1994","unstructured":"Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C et al (1994) Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 90(1):61\u201368. https:\/\/doi.org\/10.1161\/01.CIR.90.1.61","journal-title":"Circulation"},{"issue":"3","key":"2821_CR4","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1093\/cvr\/cvp066","volume":"82","author":"JI Borissoff","year":"2009","unstructured":"Borissoff JI, Spronk HMH, Heeneman S, ten Cate H (2009) Is thrombin a key player in the \u2018coagulation-atherogenesis\u2019 maze? Cardiovascular Res 82(3):392\u2013403. https:\/\/doi.org\/10.1093\/cvr\/cvp066","journal-title":"Cardiovascular Res"},{"issue":"4","key":"2821_CR5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.7326\/0003-4819-143-4-200508160-00005","volume":"143","author":"MB Rothberg","year":"2005","unstructured":"Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR (2005) Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 143(4):241\u2013250. https:\/\/doi.org\/10.7326\/0003-4819-143-4-200508160-00005","journal-title":"Ann Intern Med"},{"issue":"13","key":"2821_CR6","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1056\/NEJMoa020496","volume":"347","author":"M Hurlen","year":"2002","unstructured":"Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H, Warfarin (2002) Aspirin, or both after myocardial infarction. N Engl J Med 347(13):969\u2013974. https:\/\/doi.org\/10.1056\/NEJMoa020496","journal-title":"N Engl J Med"},{"issue":"3","key":"2821_CR7","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ehj.2003.10.026","volume":"25","author":"J Herlitz","year":"2004","unstructured":"Herlitz J, Holm J, Peterson M, Karlson BW, Haglid Evander M, Erhardt L et al (2004) Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction: the LoWASA Study. Eur Heart J 25(3):232\u2013239. https:\/\/doi.org\/10.1016\/j.ehj.2003.10.026","journal-title":"Eur Heart J"},{"issue":"3","key":"2821_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa065959","volume":"357","author":"S Anand","year":"2007","unstructured":"Anand S, Yusuf S, Xie C, Pogue J, Eikelboom J, Budaj A et al (2007) Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 357(3):217\u2013227. https:\/\/doi.org\/10.1056\/NEJMoa065959","journal-title":"N Engl J Med"},{"issue":"12","key":"2821_CR9","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1161\/circulationaha.108.801753","volume":"119","author":"BM Massie","year":"2009","unstructured":"Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M et al (2009) Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart failure (WATCH) trial. Circulation 119(12):1616\u20131624. https:\/\/doi.org\/10.1161\/circulationaha.108.801753","journal-title":"Circulation"},{"issue":"1","key":"2821_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","volume":"53","author":"W Mueck","year":"2014","unstructured":"Mueck W, Stampfuss J, Kubitza D, Becka M (2014) Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 53(1):1\u201316. https:\/\/doi.org\/10.1007\/s40262-013-0100-7","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"2821_CR11","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"V Aboyans","year":"2018","unstructured":"Aboyans V, Ricco JB, Bartelink MEL, Bj\u00f6rck M, Brodmann M, Cohnert T et al (2018) 2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial Diseases, in collaboration with the european society for vascular surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the european Stroke Organization (ESO)the Task Force for the diagnosis and treatment of peripheral arterial Diseases of the European Society of Cardiology (ESC) and of the european society for vascular surgery (ESVS). Eur Heart J 39(9):763\u2013816. https:\/\/doi.org\/10.1093\/eurheartj\/ehx095","journal-title":"Eur Heart J"},{"key":"2821_CR12","doi-asserted-by":"publisher","unstructured":"Brott TG, Halperin JL, Abbara S, Bacharach JM, Barr JD, Bush RL, American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons (2011) ASA\/ACCF\/AHA\/AANN\/AANS\/ACR\/ASNR\/CNS\/SAIP\/SCAI\/SIR\/SNIS\/SVM\/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary. A report of the, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. Circulation. 2011;124(4):489\u2013532. https:\/\/doi.org\/10.1161\/CIR.0b013e31820d8d78","DOI":"10.1161\/CIR.0b013e31820d8d78"},{"issue":"12","key":"2821_CR13","doi-asserted-by":"publisher","first-page":"e726","DOI":"10.1161\/cir.0000000000000471","volume":"135","author":"MD Gerhard-Herman","year":"2017","unstructured":"Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE et al (2017) 2016 AHA\/ACC Guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 135(12):e726\u2013e79. https:\/\/doi.org\/10.1161\/cir.0000000000000471","journal-title":"Circulation"},{"issue":"34","key":"2821_CR14","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M et al (2021) 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J 42(34):3227\u20133337. https:\/\/doi.org\/10.1093\/eurheartj\/ehab484","journal-title":"Eur Heart J"},{"key":"2821_CR15","doi-asserted-by":"publisher","unstructured":"Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, ACCF\/AHA\/ACP\/AATS et al (2012) \/PCNA\/SCAI\/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. Journal of the American College of Cardiology. 2012;60(24):e44-e164. doi:https:\/\/doi.org\/10.1016\/j.jacc.2012.07.013","DOI":"10.1016\/j.jacc.2012.07.013"},{"issue":"14","key":"2821_CR16","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","volume":"377","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O et al (2017) Rivaroxaban with or without aspirin in stable Cardiovascular Disease. N Engl J Med 377(14):1319\u20131330. https:\/\/doi.org\/10.1056\/NEJMoa1709118","journal-title":"N Engl J Med"},{"issue":"10117","key":"2821_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/s0140-6736(17)32458-3","volume":"391","author":"SJ Connolly","year":"2018","unstructured":"Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F et al (2018) Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 391(10117):205\u2013218. https:\/\/doi.org\/10.1016\/s0140-6736(17)32458-3","journal-title":"Lancet"},{"issue":"10117","key":"2821_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/s0140-6736(17)32409-1","volume":"391","author":"SS Anand","year":"2018","unstructured":"Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P et al (2018) Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 391(10117):219\u2013229. https:\/\/doi.org\/10.1016\/s0140-6736(17)32409-1","journal-title":"Lancet"},{"issue":"1","key":"2821_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1001\/jamacardio.2020.4390","volume":"6","author":"E Kaplovitch","year":"2021","unstructured":"Kaplovitch E, Eikelboom JW, Dyal L, Aboyans V, Abola MT, Verhamme P et al (2021) Rivaroxaban and aspirin in patients with symptomatic Lower Extremity Peripheral Artery Disease: a subanalysis of the COMPASS randomized clinical trial. JAMA Cardiol 6(1):21\u201329. https:\/\/doi.org\/10.1001\/jamacardio.2020.4390","journal-title":"JAMA Cardiol"},{"issue":"23","key":"2821_CR20","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1161\/circulationaha.120.046448","volume":"141","author":"DL Bhatt","year":"2020","unstructured":"Bhatt DL, Eikelboom JW, Connolly SJ, Steg PG, Anand SS, Verma S et al (2020) Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: insights from the COMPASS trial. Circulation 141(23):1841\u20131854. https:\/\/doi.org\/10.1161\/circulationaha.120.046448","journal-title":"Circulation"},{"issue":"18","key":"2821_CR21","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/j.jacc.2019.02.048","volume":"73","author":"KAA Fox","year":"2019","unstructured":"Fox KAA, Eikelboom JW, Shestakovska O, Connolly SJ, Metsarinne KP, Yusuf S (2019) Rivaroxaban Plus aspirin in patients with vascular disease and renal dysfunction: from the COMPASS trial. J Am Coll Cardiol 73(18):2243\u20132250. https:\/\/doi.org\/10.1016\/j.jacc.2019.02.048","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2821_CR22","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.jacc.2020.11.061","volume":"77","author":"TJ Guzik","year":"2021","unstructured":"Guzik TJ, Ramasundarahettige C, Pogosova N, Lopez-Jaramillo P, Dyal L, Berkowitz SD et al (2021) Rivaroxaban Plus aspirin in obese and overweight patients with vascular disease in the COMPASS trial. J Am Coll Cardiol 77(5):511\u2013525. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.061","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"2821_CR23","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1161\/circulationaha.119.039609","volume":"140","author":"KR Branch","year":"2019","unstructured":"Branch KR, Probstfield JL, Eikelboom JW, Bosch J, Maggioni AP, Cheng RK et al (2019) Rivaroxaban with or without aspirin in patients with heart failure and chronic coronary or peripheral artery disease. Circulation 140(7):529\u2013537. https:\/\/doi.org\/10.1161\/circulationaha.119.039609","journal-title":"Circulation"},{"issue":"5","key":"2821_CR24","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1093\/ehjcvp\/pvab050","volume":"8","author":"T Vanassche","year":"2022","unstructured":"Vanassche T, Verhamme P, Anand SS, Shestakovska O, Leong DP, Fox KAA et al (2022) Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. Eur Heart J Cardiovasc Pharmacother 8(5):462\u2013473. https:\/\/doi.org\/10.1093\/ehjcvp\/pvab050","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"14","key":"2821_CR25","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1161\/circulationaha.119.044598","volume":"141","author":"KR Bainey","year":"2020","unstructured":"Bainey KR, Welsh RC, Connolly SJ, Marsden T, Bosch J, Fox KAA et al (2020) Rivaroxaban Plus Aspirin Versus aspirin alone in patients with prior percutaneous coronary intervention (COMPASS-PCI). Circulation 141(14):1141\u20131151. https:\/\/doi.org\/10.1161\/circulationaha.119.044598","journal-title":"Circulation"},{"issue":"2","key":"2821_CR26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jacc.2018.10.048","volume":"73","author":"A Lamy","year":"2019","unstructured":"Lamy A, Eikelboom J, Sheth T, Connolly S, Bosch J, Fox KAA et al (2019) Rivaroxaban, aspirin, or both to prevent early coronary bypass graft occlusion: the COMPASS-CABG study. J Am Coll Cardiol 73(2):121\u2013130. https:\/\/doi.org\/10.1016\/j.jacc.2018.10.048","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2821_CR27","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1161\/circulationaha.120.046048","volume":"142","author":"J Steffel","year":"2020","unstructured":"Steffel J, Eikelboom JW, Anand SS, Shestakovska O, Yusuf S, Fox KAA (2020) The COMPASS trial: net clinical benefit of low-dose Rivaroxaban Plus aspirin as compared with aspirin in patients with chronic vascular disease. Circulation 142(1):40\u201348. https:\/\/doi.org\/10.1161\/circulationaha.120.046048","journal-title":"Circulation"},{"key":"2821_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/ehjqcco\/qcac054","author":"A Lamy","year":"2022","unstructured":"Lamy A, Eikelboom J, Tong W, Yuan F, Bangdiwala SI, Bosch J et al (2022) The cost-effectiveness of Rivaroxaban with or without aspirin in the COMPASS trial. Eur Heart J Qual Care Clin Outcomes. https:\/\/doi.org\/10.1093\/ehjqcco\/qcac054","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"20","key":"2821_CR29","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1056\/NEJMoa1202299","volume":"366","author":"S Homma","year":"2012","unstructured":"Homma S, Thompson JLP, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR et al (2012) Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 366(20):1859\u20131869. https:\/\/doi.org\/10.1056\/NEJMoa1202299","journal-title":"N Engl J Med"},{"issue":"14","key":"2821_CR30","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1056\/NEJMoa1808848","volume":"379","author":"F Zannad","year":"2018","unstructured":"Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade M et al (2018) Rivaroxaban in patients with heart failure, Sinus Rhythm, and Coronary Disease. N Engl J Med 379(14):1332\u20131342. https:\/\/doi.org\/10.1056\/NEJMoa1808848","journal-title":"N Engl J Med"},{"issue":"21","key":"2821_CR31","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","volume":"382","author":"MP Bonaca","year":"2020","unstructured":"Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR et al (2020) Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med 382(21):1994\u20132004. https:\/\/doi.org\/10.1056\/NEJMoa2000052","journal-title":"N Engl J Med"},{"issue":"39","key":"2821_CR32","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1093\/eurheartj\/ehab408","volume":"42","author":"MJ Krantz","year":"2021","unstructured":"Krantz MJ, Debus SE, Hsia J, Patel MR, Anand SS, Nehler MR et al (2021) Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. Eur Heart J 42(39):4040\u20134048. https:\/\/doi.org\/10.1093\/eurheartj\/ehab408","journal-title":"Eur Heart J"},{"issue":"12","key":"2821_CR33","doi-asserted-by":"publisher","first-page":"e024655","DOI":"10.1161\/jaha.121.024655","volume":"11","author":"CN Hess","year":"2022","unstructured":"Hess CN, Baumgartner I, Anand SS, Nehler MR, Patel MR, Debus ES et al (2022) Sex-based differences in outcomes following peripheral artery revascularization: insights from VOYAGER PAD. J Am Heart Assoc 11(12):e024655. https:\/\/doi.org\/10.1161\/jaha.121.024655","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"2821_CR34","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2017","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H et al (2017) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39(2):119\u2013177. https:\/\/doi.org\/10.1093\/eurheartj\/ehx393","journal-title":"Eur Heart J"},{"issue":"14","key":"2821_CR35","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"JP Collet","year":"2021","unstructured":"Collet JP, Thiele H, Barbato E, Barth\u00e9l\u00e9my O, Bauersachs J, Bhatt DL et al (2021) 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 42(14):1289\u20131367. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa575","journal-title":"Eur Heart J"},{"issue":"3","key":"2821_CR36","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1161\/cir.0000000000001039","volume":"145","author":"JS Lawton","year":"2022","unstructured":"Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM et al (2022) 2021 ACC\/AHA\/SCAI Guideline for Coronary Artery revascularization: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145(3):e4\u2013e17. https:\/\/doi.org\/10.1161\/cir.0000000000001039","journal-title":"Circulation"},{"issue":"1","key":"2821_CR37","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJMe1112770","volume":"366","author":"MT Roe","year":"2011","unstructured":"Roe MT, Ohman EM (2011) A new era in secondary Prevention after Acute Coronary Syndrome. N Engl J Med 366(1):85\u201387. https:\/\/doi.org\/10.1056\/NEJMe1112770","journal-title":"N Engl J Med"},{"issue":"10081","key":"2821_CR38","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/s0140-6736(17)30751-1","volume":"389","author":"EM Ohman","year":"2017","unstructured":"Ohman EM, Roe MT, Steg PG, James SK, Povsic TJ, White J et al (2017) Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet 389(10081):1799\u20131808. https:\/\/doi.org\/10.1016\/s0140-6736(17)30751-1","journal-title":"Lancet"},{"issue":"1","key":"2821_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa1112277","volume":"366","author":"JL Mega","year":"2012","unstructured":"Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C et al (2012) Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366(1):9\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1112277","journal-title":"N Engl J Med"},{"issue":"4","key":"2821_CR40","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jacc.2013.03.041","volume":"62","author":"CM Gibson","year":"2013","unstructured":"Gibson CM, Chakrabarti AK, Mega J, Bode C, Bassand JP, Verheugt FW et al (2013) Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. J Am Coll Cardiol 62(4):286\u2013290. https:\/\/doi.org\/10.1016\/j.jacc.2013.03.041","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"2821_CR41","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.jcin.2022.01.285","volume":"15","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Si D, Zhang Q, Jin L, Zheng H, Qu M et al (2022) Prophylactic Rivaroxaban Therapy for Left ventricular Thrombus after Anterior ST-Segment Elevation myocardial infarction. JACC Cardiovasc Interv 15(8):861\u2013872. https:\/\/doi.org\/10.1016\/j.jcin.2022.01.285","journal-title":"JACC Cardiovasc Interv"},{"issue":"2","key":"2821_CR42","doi-asserted-by":"publisher","first-page":"e2255709","DOI":"10.1001\/jamanetworkopen.2022.55709","volume":"6","author":"S Zhou","year":"2023","unstructured":"Zhou S, Xiao Y, Zhou C, Zheng Z, Jiang W, Shen Q et al (2023) Effect of Rivaroxaban vs Enoxaparin on Major Cardiac adverse events and bleeding risk in the Acute phase of Acute Coronary Syndrome: the H-REPLACE Randomized Equivalence and Noninferiority Trial. JAMA Netw Open 6(2):e2255709\u2013e. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.55709","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2821_CR43","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s11239-020-02114-7","volume":"50","author":"SU Khan","year":"2020","unstructured":"Khan SU, Khan MZ, Asad ZUA, Valavoor S, Khan MU, Khan MS et al (2020) Efficacy and safety of low dose rivaroxaban in patients with coronary heart disease: a systematic review and meta-analysis. J Thromb Thrombolysis 50(4):913\u2013920. https:\/\/doi.org\/10.1007\/s11239-020-02114-7","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"2821_CR44","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","volume":"3","author":"E Perzborn","year":"2005","unstructured":"Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH et al (2005) In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939\u2013an oral, direct factor xa inhibitor. J Thromb Haemost 3(3):514\u2013521. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01166.x","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2821_CR45","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1177\/1074248415578172","volume":"20","author":"E Perzborn","year":"2015","unstructured":"Perzborn E, Heitmeier S, Laux V (2015) Effects of Rivaroxaban on platelet activation and platelet-coagulation Pathway Interaction: in Vitro and in vivo studies. J Cardiovasc Pharmacol Ther 20(6):554\u2013562. https:\/\/doi.org\/10.1177\/1074248415578172","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"3","key":"2821_CR46","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s11239-018-1709-z","volume":"46","author":"J Sokol","year":"2018","unstructured":"Sokol J, Nehaj F, Ivankova J, Mokan M, Mokan M (2018) First evidence: rivaroxaban and apixaban reduce thrombin-dependent platelet aggregation. J Thromb Thrombolysis 46(3):393\u2013398. https:\/\/doi.org\/10.1007\/s11239-018-1709-z","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"2821_CR47","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/fjc.0000000000000770","volume":"75","author":"J Hernandez-Juarez","year":"2020","unstructured":"Hernandez-Juarez J, Espejo-Godinez HG, Mancilla-Padilla R, Hernandez-Lopez JR, Moreno JAA, Majluf-Cruz K et al (2020) Effects of Rivaroxaban on platelet aggregation. J Cardiovasc Pharmacol 75(2):180\u2013184. https:\/\/doi.org\/10.1097\/fjc.0000000000000770","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"2821_CR48","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1161\/atvbaha.107.150474","volume":"28","author":"D Varga-Szabo","year":"2008","unstructured":"Varga-Szabo D, Pleines I, Nieswandt B (2008) Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol 28(3):403\u2013412. https:\/\/doi.org\/10.1161\/atvbaha.107.150474","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"2821_CR49","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/eurheartj\/ehp504","volume":"31","author":"DJ Angiolillo","year":"2010","unstructured":"Angiolillo DJ, Capodanno D, Goto S (2010) Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J 31(1):17\u201328. https:\/\/doi.org\/10.1093\/eurheartj\/ehp504","journal-title":"Eur Heart J"},{"issue":"4","key":"2821_CR50","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1253\/circj.cj-09-0982","volume":"74","author":"DJ Angiolillo","year":"2010","unstructured":"Angiolillo DJ, Ueno M, Goto S (2010) Basic principles of platelet biology and clinical implications. Circ J 74(4):597\u2013607. https:\/\/doi.org\/10.1253\/circj.cj-09-0982","journal-title":"Circ J"},{"issue":"3","key":"2821_CR51","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1055\/s-0035-1564835","volume":"42","author":"T Gremmel","year":"2016","unstructured":"Gremmel T, Frelinger AL 3rd, Michelson AD (2016) Platelet physiology. Semin Thromb Hemost 42(3):191\u2013204. https:\/\/doi.org\/10.1055\/s-0035-1564835","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"2821_CR52","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1182\/blood.v100.1.148","volume":"100","author":"KE Brummel","year":"2002","unstructured":"Brummel KE, Paradis SG, Butenas S, Mann KG (2002) Thrombin functions during tissue factor-induced blood coagulation. Blood 100(1):148\u2013152. https:\/\/doi.org\/10.1182\/blood.v100.1.148","journal-title":"Blood"},{"issue":"6694","key":"2821_CR53","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/29325","volume":"394","author":"ML Kahn","year":"1998","unstructured":"Kahn ML, Zheng YW, Huang W, Bigornia V, Zeng D, Moff S et al (1998) A dual thrombin receptor system for platelet activation. Nature 394(6694):690\u2013694. https:\/\/doi.org\/10.1038\/29325","journal-title":"Nature"},{"issue":"20","key":"2821_CR54","doi-asserted-by":"publisher","first-page":"11189","DOI":"10.1073\/pnas.96.20.11189","volume":"96","author":"H Andersen","year":"1999","unstructured":"Andersen H, Greenberg DL, Fujikawa K, Xu W, Chung DW, Davie EW (1999) Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci U S A 96(20):11189\u201311193. https:\/\/doi.org\/10.1073\/pnas.96.20.11189","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2821_CR55","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1172\/jci6042","volume":"103","author":"ML Kahn","year":"1999","unstructured":"Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR (1999) Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 103(6):879\u2013887. https:\/\/doi.org\/10.1172\/jci6042","journal-title":"J Clin Invest"},{"issue":"4","key":"2821_CR56","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1161\/circresaha.119.315099","volume":"126","author":"T Petzold","year":"2020","unstructured":"Petzold T, Thienel M, Dannenberg L, Mourikis P, Helten C, Ayhan A et al (2020) Rivaroxaban reduces arterial thrombosis by inhibition of FXa-Driven platelet activation via protease activated Receptor-1. Circ Res 126(4):486\u2013500. https:\/\/doi.org\/10.1161\/circresaha.119.315099","journal-title":"Circ Res"},{"issue":"10","key":"2821_CR57","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.molmed.2008.08.001","volume":"14","author":"K Borensztajn","year":"2008","unstructured":"Borensztajn K, Peppelenbosch MP, Spek CA (2008) Factor xa: at the crossroads between coagulation and signaling in physiology and disease. Trends Mol Med 14(10):429\u2013440. https:\/\/doi.org\/10.1016\/j.molmed.2008.08.001","journal-title":"Trends Mol Med"},{"issue":"2","key":"2821_CR58","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1476-5381.2010.00705.x","volume":"160","author":"UJ Soh","year":"2010","unstructured":"Soh UJ, Dores MR, Chen B, Trejo J (2010) Signal transduction by protease-activated receptors. Br J Pharmacol 160(2):191\u2013203. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.00705.x","journal-title":"Br J Pharmacol"},{"issue":"3","key":"2821_CR59","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1093\/cvr\/cvt343","volume":"101","author":"HM Spronk","year":"2014","unstructured":"Spronk HM, de Jong AM, Crijns HJ, Schotten U, Van Gelder IC, Ten Cate H (2014) Pleiotropic effects of factor xa and thrombin: what to expect from novel anticoagulants. Cardiovasc Res 101(3):344\u2013351. https:\/\/doi.org\/10.1093\/cvr\/cvt343","journal-title":"Cardiovasc Res"},{"issue":"4","key":"2821_CR60","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1160\/th13-09-0730","volume":"111","author":"CT Esmon","year":"2014","unstructured":"Esmon CT (2014) Targeting factor xa and thrombin: impact on coagulation and beyond. Thromb Haemost 111(4):625\u2013633. https:\/\/doi.org\/10.1160\/th13-09-0730","journal-title":"Thromb Haemost"},{"issue":"4","key":"2821_CR61","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41569-019-0314-y","volume":"17","author":"D Capodanno","year":"2020","unstructured":"Capodanno D, Bhatt DL, Eikelboom JW, Fox KAA, Geisler T, Michael Gibson C et al (2020) Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nat Reviews Cardiol 17(4):242\u2013257. https:\/\/doi.org\/10.1038\/s41569-019-0314-y","journal-title":"Nat Reviews Cardiol"},{"issue":"3","key":"2821_CR62","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1517\/14728222.2011.553608","volume":"15","author":"K Borensztajn","year":"2011","unstructured":"Borensztajn K, Spek CA (2011) Blood coagulation factor xa as an emerging drug target. Expert Opin Ther Targets 15(3):341\u2013349. https:\/\/doi.org\/10.1517\/14728222.2011.553608","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"2821_CR63","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1038\/s41598-019-40602-w","volume":"9","author":"JJ Posthuma","year":"2019","unstructured":"Posthuma JJ, Posma JJN, van Oerle R, Leenders P, van Gorp RH, Jaminon AMG et al (2019) Targeting coagulation factor Xa promotes regression of Advanced atherosclerosis in Apolipoprotein-E deficient mice. Sci Rep 9(1):3909. https:\/\/doi.org\/10.1038\/s41598-019-40602-w","journal-title":"Sci Rep"},{"issue":"39","key":"2821_CR64","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1093\/eurheartj\/ehab390","volume":"42","author":"V Aboyans","year":"2021","unstructured":"Aboyans V, Bauersachs R, Mazzolai L, Brodmann M, Palomares JFR, Debus S et al (2021) Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. Eur Heart J 42(39):4013\u20134024. https:\/\/doi.org\/10.1093\/eurheartj\/ehab390","journal-title":"Eur Heart J"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-023-02821-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-023-02821-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-023-02821-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T08:12:34Z","timestamp":1687335154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-023-02821-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,6]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["2821"],"URL":"https:\/\/doi.org\/10.1007\/s11239-023-02821-x","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,6]]},"assertion":[{"value":"16 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DC reports speaker\u2019s or consulting fees from Amgen, Arena, Daiichi Sankyo, Sanofi, Terumo, and institutional fees from Medtronic. PMM has nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}